Xem ngay gi pha di t Hasaki chn cho mnh mt sn phm cht lng nh
Schizophyllan Inhibits the Development of Mammary and Hepatic Carcinomas Induced by 7,12 Dimethylbenz()anthracene and Decreases Cell Proliferation: Comparison with Tamoxifen
10.1097/CORR.0000000000001555 98 WanR.HussainA.BehfarA.MoranS
for more information, see Supplementary Table 1)) / Metainformation_Ions (All needed metainformation of annotated ions (Annotation, Ion m / z , Annotation IDs)) / mean log2-FC (Dynamic metabolic changes during drug treatments (mean log 2 FC) relative to unperturbed cancer cells (A549wt, A549NR3C1 knockout, timepoint 1 (1 h), timepoint 2 (5 h), timepoint 3 (24 h), timepoint 4 (48 h), for enzyme inhibitors: drug concentration 1 M, 10 M, 50 M, for GCR agonists: drug concentration 10 M)) / z-scores (z-score normalized mean log 2 FC (A549wt, A549NR3C1 knockout, timepoint 1 (1 h), timepoint 2 (5 h), timepoint 3 (24 h), timepoint 4 (48 h), for enzyme inhibitors: drug concentration 1 M, 10 M, 50 M, for GCR agonists: drug concentration 10 M)) / standard deviation (Standard deviation of mean log 2 FC values during drug treatments (A549wt, A549NR3C1 knockout, timepoint 1 (1 h), timepoint 2 (5 h), timepoint 3 (24 h), timepoint 4 (48 h), for enzyme inhibitors: drug concentration 1 M, 10 M and 50 M, for GCR agonists: drug concentration 10 M)) / p-values (Statistical significance ( P value, t -test) of metabolic changes during drug treatments (A549wt, A549NR3C1 knockout, timepoint 1 (1 h), timepoint 2 (5 h), timepoint 3 (24 h), timepoint 4 (48 h), for enzyme inhibitors: drug concentration 1 M, 10 M and 50 M, for GCR agonists: drug concentration 10 M)) / q-values (Adjusted statistical significance (BHFR) of metabolic changes during drug treatments (A549wt, A549NR3C1 knockout, timepoint 1 (1 h), timepoint 2 (5 h), timepoint 3 (24 h), timepoint 4 (48 h), for enzyme inhibitors: drug concentration 1 M, 10 M and 50 M, for GCR agonists: drug concentration 10 M)) / TTest_GCR_wt_KO_Signature ( P values and mean z-score per metabolite across all six retested GCR agonists against all non-GCR drugs profilied in the initial Prestwick library screen, seperately analyzed in A549wt and A549 NR3C1 knockout cells) / Top predictions (List of most similar 0.3% of drugdrug pairs, with drug name, drug MoA, drug therapeutic class and drugdrug similarity scores)
